Metin YİLDİRİM, Mehmet ERSATİR, Badel ARSLAN, Elife Sultan GİRAY

Cytotoxic and apoptotic potential of some coumarin and 2-amino-3-carbonitrile selenophene derivatives in prostate cancer

3-acetyl coumarin derivatives (1a-d) are formed as a result of condensation of salicylaldehyde derivatives and ethyl acetoacetate and were converted into coumarin-selenophene hybrid compounds (2a-d) in the basic medium by modified Gewald reaction in the presence of malononitrile and selenium. Products are characterized by nuclear magnetic resonance (NMR). The prepared compounds are screened for their anticancer activity against DU-145 cell line. In addition, selected target compounds are evaluated for apoptosis and oxidative stress on DU-145 (prostate carcinoma) cell lines.

Keywords:

Coumarin selenophene, antitumor agents, antioxidant activity, heterocycles,

PDF

___

Akkol EK, 2020, CANCERS, V12, DOI 10.3390/cancers12071959
Amin KM, 2008, BIOORGAN MED CHEM, V16, P5377, DOI 10.1016/j.bmc.2008.04.021
Anand P, 2013, ARCH PHARM RES, V36, P375, DOI 10.1007/s12272-013-0036-3
BEUTLER E, 1963, EXPERIENTIA, V19, P96, DOI 10.1007/BF02148042
Bui CT, 2006, J COMB CHEM, V8, P163, DOI 10.1021/cc050066w
Catto M, 2013, BIOORGAN MED CHEM, V21, P146, DOI 10.1016/j.bmc.2012.10.045
Circu ML, 2008, FREE RADICAL RES, V42, P689, DOI 10.1080/10715760802317663
Curini M, 2003, AUST J CHEM, V56, P59, DOI 10.1071/CH02177
de Souza LG, 2016, CHEM-BIOL INTERACT, V254, P11, DOI 10.1016/j.cbi.2016.05.001
Dominguez-Alvarez E, 2016, BIOORG MED CHEM LETT, V26, P2821, DOI 10.1016/j.bmcl.2016.04.064
Domracheva I, 2017, LIFE SCI, V186, P92, DOI 10.1016/j.lfs.2017.08.011
Ebrahimi SES, 2016, MED CHEM RES, V25, P1831, DOI 10.1007/s00044-016-1626-7
Emami S, 2015, EUR J MED CHEM, V102, P611, DOI 10.1016/j.ejmech.2015.08.033
Ersatir M, 2021, SYNTHETIC COMMUN, V51, P290, DOI 10.1080/00397911.2020.1825744
Ersatir M, 2020, MONATSH CHEM, V151, P625, DOI 10.1007/s00706-020-02573-x
Ersatir M, 2017, SYNTHETIC COMMUN, V47, P68, DOI 10.1080/00397911.2016.1252047
Fallarero A, 2008, PHARMACOL RES, V58, P215, DOI 10.1016/j.phrs.2008.08.001
Gandin V, 2018, FREE RADICAL BIO MED, V127, P80, DOI 10.1016/j.freeradbiomed.2018.05.001
Hacioglu C, 2020, BIOL TRACE ELEM RES, V195, P436, DOI 10.1007/s12011-019-01879-0
Hamulakova S, 2014, J MED CHEM, V57, P7073, DOI 10.1021/jm5008648
Hassan MZ, 2016, EUR J MED CHEM, V123, P236, DOI 10.1016/j.ejmech.2016.07.056
Hejchman E, 2015, PHARMACOL REP, V67, P236, DOI 10.1016/j.pharep.2014.09.008
Jain P. K., 2012, Journal of Applied Pharmaceutical Science, V2, P236
Kar F, 2019, CELL STRESS CHAPERON, V24, P871, DOI 10.1007/s12192-019-01022-x
Kim DH, 2016, MOL CARCINOGEN, V55, P1096, DOI 10.1002/mc.22353
Mirunalini S., 2014, BIOMED AGING PATHOL, V4, P131, DOI [10.1016/j.biomag.2014.01.006, DOI 10.1016/J.BIOMAG.2014.01.006]
Muller-Schiffmann A, 2012, BIODRUGS, V26, P21, DOI 10.2165/11597630-000000000-00000
MYERS RB, 1994, J CANCER RES CLIN, V120, pS11, DOI 10.1007/BF01377115
OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
Reddy NS, 2004, BIOORG MED CHEM LETT, V14, P4093, DOI 10.1016/j.bmcl.2004.05.016
Shiah HS, 2007, BIOCHEM PHARMACOL, V73, P610, DOI 10.1016/j.bcp.2006.10.019
Siddiqui N, 2009, ACTA POL PHARM, V66, P161
Tung DT, 2008, ADV SYNTH CATAL, V350, P2109, DOI 10.1002/adsc.200800316
Umar S, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22553
Waterborg JH, 2019, LOWRY METHOD PROTEIN
Wiles JA, 2011, J MED CHEM, V54, P3418, DOI 10.1021/jm2002124
Zhang LF, 2019, EUR J MED CHEM, V181, DOI 10.1016/j.ejmech.2019.111587